List of Excipients in Branded Drug LEVOCETIRIZINE

Generic Drugs Containing LEVOCETIRIZINE

Company	Ingredient	NDC	Excipient
Walgreen Company	levocetirizine dihydrochloride	0363-2241	CELLULOSE, MICROCRYSTALLINE
Walgreen Company	levocetirizine dihydrochloride	0363-2241	HYPROMELLOSE
Walgreen Company	levocetirizine dihydrochloride	0363-2241	LACTOSE MONOHYDRATE
Walgreen Company	levocetirizine dihydrochloride	0363-2241	MAGNESIUM STEARATE
Walgreen Company	levocetirizine dihydrochloride	0363-2241	POLYETHYLENE GLYCOL
Walgreen Company	levocetirizine dihydrochloride	0363-2241	TITANIUM DIOXIDE
Teva Pharmaceuticals USA Inc	levocetirizine dihydrochloride	0093-7701	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in LEVOCETIRIZINE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSE
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL
1	TITANIUM DIOXIDE

Levocetirizine Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Levocetirizine is a mature, low-cost antihistamine with limited active-ingredient exclusivity. Commercial differentiation depends on excipient selection, dosage-form convenience, pediatric acceptability, preservative strategy, packaging, and regulatory execution rather than new-molecule patent protection. The strongest opportunities are sugar-free pediatric liquids, rapidly disintegrating tablets, unit-dose formats, and products designed for patients avoiding lactose, certain dyes, or selected preservatives.

What is the regulatory and commercial status of levocetirizine?

Levocetirizine dihydrochloride is the active ingredient in prescription and over-the-counter products used for allergic rhinitis and chronic urticaria. The reference brand is Xyzal, originally commercialized by UCB and later marketed in the United States through other commercial partners.

The drug is a small molecule, not a biologic. Biosimilar regulation does not apply. Generic competition proceeds through abbreviated new drug applications, or ANDAs, rather than biosimilar applications.

Attribute	Levocetirizine
Active ingredient	Levocetirizine dihydrochloride
Pharmacologic class	Second-generation H1 antihistamine
Common tablet strength	5 mg
Common oral-solution strength	0.5 mg/mL
Principal indications	Allergic rhinitis and chronic urticaria
U.S. regulatory pathways	NDA, ANDA, OTC monograph-based pathways where applicable
Biosimilar exposure	None
Primary commercial competition	Generic tablets, oral solutions, cetirizine, loratadine, fexofenadine
Main differentiation levers	Taste, swallowability, excipient profile, packaging, price, channel access

The product has a large installed generic base. As a result, an excipient strategy must solve a defined patient or channel problem. A minor change in tablet color or coating is unlikely to create durable value unless it supports a recognized consumer or regulatory claim.

What excipients are used in levocetirizine tablets?

Immediate-release levocetirizine tablets generally use conventional direct-compression or wet-granulation excipients. Product-specific inactive ingredients vary by manufacturer and strength.

Common excipient categories include:

Excipient category	Typical function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports robust low-dose tablet manufacture
Lactose monohydrate	Filler and binder	Cost-efficient, but unsuitable for some lactose-avoidant consumers
Mannitol	Diluent and mouthfeel modifier	Useful for chewable and orally disintegrating products
Croscarmellose sodium or crospovidone	Superdisintegrant	Supports rapid tablet breakup
Povidone	Binder	Improves granule strength
Colloidal silicon dioxide	Glidant	Improves powder flow
Magnesium stearate	Lubricant	Controls ejection force and sticking
Hypromellose	Film former	Enables coating and swallowability improvements
Polyethylene glycol or macrogol	Coating plasticizer	Improves coating flexibility
Titanium dioxide or iron oxides	Opacifier or colorant	Supports product identification and branding

DailyMed listings show that inactive ingredients differ among levocetirizine products. Formulators must therefore treat the reference product’s composition, target release profile, manufacturing process, and stability data as separate development inputs rather than assume a universal formulation standard.[1]

What tablet excipient strategy is most commercially attractive?

For a conventional 5 mg tablet, the lowest-risk strategy is a standard immediate-release composition using microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide, magnesium stearate, and a film coat. This approach minimizes development risk and supports high-throughput manufacturing.

The most commercially useful modifications are:

1. Lactose-free substitution with mannitol, cellulose, calcium phosphate, or another suitable diluent.
2. Reduced tablet weight for easier swallowing.
3. Fast disintegration without changing dissolution or bioequivalence.
4. Lower friability for bottles, blister packs, and e-commerce distribution.
5. Dye-free or low-color coating systems.
6. Packaging that improves moisture protection without raising unit cost materially.

The excipient portfolio should be selected with the finished product label in mind. A formulation marketed as lactose-free, dye-free, sugar-free, or suitable for a defined dietary preference must have supplier and manufacturing controls that support the claim.

What excipients are used in levocetirizine oral solution?

Levocetirizine oral solutions commonly use a water-based vehicle with sweeteners, preservatives, pH-control agents, and viscosity or mouthfeel modifiers. One U.S. reference formulation lists glycerin, propylene glycol, methylparaben, sodium acetate, acetic acid, sucralose, and purified water among its inactive ingredients.[2]

The main formulation constraints are taste, preservative efficacy, chemical stability, microbial control, and pediatric dosing accuracy.

Formulation need	Potential excipient approach	Key risk
Sweetness	Sucralose, sorbitol, sucrose, acesulfame potassium	Aftertaste, laxation, sugar claims
Body and mouthfeel	Glycerin, sorbitol, propylene glycol	Viscosity, gastrointestinal tolerance
Preservation	Methylparaben, propylparaben, potassium sorbate, sodium benzoate	pH dependence and consumer acceptance
Buffering	Acetate, citrate, phosphate systems	Stability and taste impact
Solubilization	Propylene glycol or other cosolvent systems	Pediatric exposure limits and labeling
Flavor masking	Fruit flavors, cooling agents, bitterness blockers	Stability and sensory compatibility
Microbial control	Preservative system plus validated packaging	In-use stability and contamination risk

How can manufacturers improve levocetirizine liquid formulations?

The strongest liquid opportunity is a sugar-free, pleasant-tasting product with a low-viscosity profile and a calibrated oral syringe. Pediatric caregivers generally value dosing accuracy, low mess, and acceptable taste more than marginal changes in pharmacokinetics.

A development program should test:

• Sweetener combinations rather than a single high-intensity sweetener.
• Bitter-blocking flavors compatible with the active ingredient.
• Preservative systems across the intended pH range.
• Sedimentation and dose uniformity if suspensions are considered.
• Chemical stability in multidose bottles.
• Extractables and leachables from bottles, closures, and oral syringes.
• In-use stability after opening.
• Compatibility with unit-dose sachets or small-volume bottles.

A preservative-free multidose liquid is commercially attractive but technically more difficult. It may require a unit-dose container, aseptic manufacture, antimicrobial packaging, or a validated alternative preservation strategy. The additional packaging and manufacturing cost must be offset by a defined market segment, such as pediatric, allergy-sensitive, or institutional use.

What formulation patents can protect levocetirizine products?

The active ingredient itself has limited value as an exclusivity asset because levocetirizine is a mature generic drug. Formulation and delivery patents can still protect incremental products if they claim a technically distinct and commercially relevant composition.

Potential claim areas include:

• Orally disintegrating tablets with defined disintegration and dissolution limits.
• Taste-masked particles or coated drug crystals.
• Low-moisture or moisture-stable tablet compositions.
• Specific excipient ratios that improve content uniformity.
• Preservative-free oral solutions in unit-dose packaging.
• Stabilized liquid formulations with defined pH and degradation limits.
• Pediatric formulations with calibrated dosing systems.
• Combination products with decongestants or other allergy therapies.
• Manufacturing processes that produce a particular particle-size distribution or tablet profile.
• Packaging systems that control moisture, oxygen, or light exposure.

A formulation patent is stronger when it ties the excipient combination to measurable performance. Claims based only on a list of routine excipients are vulnerable to obviousness and lack-of-inventive-step challenges. Useful performance parameters include disintegration time, dissolution at defined time points, impurity limits, preservative effectiveness, taste scores, content uniformity, and stability under accelerated conditions.

When does levocetirizine lose exclusivity?

Levocetirizine has already lost the practical protection associated with its original small-molecule exclusivity period in the United States. Generic levocetirizine products are widely available in tablet and oral-solution forms.

The commercial exclusivity timeline is therefore driven by:

Exclusivity element	Current commercial impact
Original active-ingredient patents	No material barrier to standard generic entry
Regulatory exclusivity	Historical rather than current for ordinary levocetirizine products
Orange Book-listed patents	Product-specific and must be checked against the current FDA listing
Formulation patents	Relevant only to protected dosage forms or compositions
Trademark rights	May protect branding but not the active ingredient
OTC switch and labeling	Can affect channel access and consumer positioning

FDA Orange Book determinations are product-specific. An Orange Book listing does not automatically block all levocetirizine products. It can affect an ANDA applicant only to the extent that the proposed product implicates a listed patent and the applicant must make an appropriate patent certification.[3]

Are Paragraph IV challenges relevant to levocetirizine?

Paragraph IV litigation is most important when an ANDA applicant seeks to enter before expiration of a listed patent. For ordinary levocetirizine tablets, the principal originator exclusivity barriers have largely elapsed, reducing the strategic value of a conventional Paragraph IV campaign.

Paragraph IV risk remains relevant for:

• New orally disintegrating formulations.
• Taste-masked pediatric products.
• Novel preservative-free liquids.
• Combination products.
• Patented delivery devices.
• Reformulated products with separate Orange Book-listed patents.

A challenger must assess whether the proposed formulation falls within the claims of any listed patent, not merely whether it contains levocetirizine. The principal legal risks are claim construction, obviousness, written description, enablement, and infringement based on formulation ratios or process limitations.

For a mature product, the more likely business strategy is a non-infringing formulation and a rapid, low-cost ANDA or OTC development program rather than expensive patent litigation.

What generic launch risks exist for levocetirizine?

Generic entry risk is high for standard tablets and conventional oral solutions. Manufacturing capacity, API sourcing, price erosion, and retailer access are more important than active-ingredient patent barriers.

Standard tablet launch

A conventional 5 mg tablet has:

• Low formulation complexity.
• Multiple potential API and excipient suppliers.
• Established analytical methods.
• Familiar dissolution and stability requirements.
• Significant price competition.
• Limited differentiation unless supported by packaging or channel strategy.

Oral-solution launch

A liquid product has higher technical and commercial barriers:

• Taste and preservative performance can determine market acceptance.
• Microbial control requires more extensive validation.
• Packaging affects dose accuracy and stability.
• Shipping weight increases logistics costs.
• Pediatric labeling and measuring-device performance require close control.

A liquid can therefore provide better margin protection than a standard tablet, although the addressable market is smaller.

What commercial opportunities exist in levocetirizine excipients?

Sugar-free pediatric oral solution

A sugar-free liquid can target pediatric allergy treatment, adult consumers avoiding sucrose, and retail channels that emphasize dietary claims. The formulation should use a controlled sweetener and flavor system, avoid excessive viscosity, and include an oral syringe rather than relying on household spoons.

Lactose-free and dye-free tablets

Lactose-free and dye-free versions can differentiate in pharmacy, hospital, mail-order, and e-commerce channels. These claims are relatively easy to communicate, but the price premium must be supported by reliable supply and clear labeling.

Orally disintegrating tablets

An orally disintegrating tablet can target patients who have difficulty swallowing, travelers, and consumers seeking water-free administration. Mannitol is often attractive because it provides a relatively clean mouthfeel, while crospovidone or croscarmellose sodium can support rapid disintegration.

The commercial challenge is protecting tablet mechanical strength during packaging, shipping, and handling. A product that disintegrates rapidly but chips or absorbs moisture has limited market value.

Unit-dose liquid and stick-pack formats

Single-use liquids or powder-for-reconstitution formats can target travel, institutional dispensing, and controlled pediatric dosing. Packaging costs are higher, so the product is most viable where convenience or contamination control supports a premium.

Combination and co-packaged allergy products

Levocetirizine can be positioned in co-packaged or combination regimens with intranasal corticosteroids, saline products, or decongestants. Combination claims create regulatory and patent complexity, particularly if the product includes pseudoephedrine or another active ingredient. A co-packaged strategy may deliver some commercial benefits while reducing fixed-dose combination development risk.

How strong is the levocetirizine patent estate?

The patent estate for standard levocetirizine tablets and oral solutions is commercially weak because the drug is mature and genericized. The strongest remaining protection, where available, is likely to arise from specific formulation, delivery, packaging, or combination claims rather than the active ingredient.

Asset type	Relative strength
Standard 5 mg immediate-release tablet	Low
Conventional oral solution	Low to moderate
Taste-masked pediatric liquid	Moderate if technically supported
Orally disintegrating tablet	Moderate
Preservative-free unit-dose liquid	Moderate to high if composition and packaging are novel
Combination product	Product-specific
Manufacturing process	Moderate if difficult to design around
Brand and trade dress	Commercially useful but not pharmaceutical exclusivity

Geographic coverage must be evaluated separately. U.S. Orange Book status, European supplementary protection certificates, national formulation patents, and freedom-to-operate positions can differ materially. A formulation company should avoid treating a U.S. patent position as evidence of protection in Europe, Canada, Japan, or emerging markets.

What licensing opportunities exist for levocetirizine products?

Licensing opportunities are more likely to involve finished products, regional rights, or formulation technology than the underlying levocetirizine molecule.

Potential deal structures include:

• Regional licensing of an OTC brand.
• Contract development and manufacturing of pediatric liquids.
• Licensing of taste-masking technology.
• Private-label supply for pharmacy and retail chains.
• Co-development of orally disintegrating tablets.
• Technology transfer for preservative-free unit-dose packaging.
• Co-promotion with intranasal allergy products.
• Supply agreements for differentiated excipient systems.

A licensor should demonstrate one of four assets: regulatory approval, proven consumer acceptance, protected formulation claims, or lower manufacturing cost. An unprotected conventional tablet is generally a supply opportunity rather than a high-value licensing asset.

What regulatory strategy is appropriate for a new levocetirizine formulation?

For a prescription product, the pathway depends on whether the product is a pharmaceutical equivalent of an approved reference product or a materially different dosage form, strength, route, or combination. An ANDA may be appropriate for an equivalent product. A new dosage form, formulation, or indication may require a different FDA submission strategy.

For OTC commercialization, the sponsor must align the formulation, labeling, dosage, active ingredient, and claims with the applicable FDA monograph framework or pursue an NDA where the product falls outside the monograph pathway.[4]

The development package should cover:

• Quantitative composition and manufacturing controls.
• Assay, impurities, content uniformity, and dissolution.
• Stability and in-use stability.
• Preservative effectiveness for multidose liquids.
• Bioequivalence where required.
• Packaging compatibility.
• Excipient safety, including pediatric exposure.
• Labeling and dosing-device performance.
• Supplier qualification and change-control procedures.

Excipient changes can alter dissolution, absorption, taste, stability, or bioequivalence. They should be managed as product-defining variables, not treated as low-risk substitutions late in development.

Key Takeaways

• Levocetirizine is a mature generic small molecule with limited standard active-ingredient exclusivity.
• Conventional 5 mg tablets face high generic competition and low patent barriers.
• The strongest commercial opportunities are pediatric liquids, orally disintegrating tablets, lactose-free products, dye-free products, and unit-dose packaging.
• Oral solutions require tighter control of taste, preservation, pH, packaging, and in-use stability.
• Formulation patents are more defensible when they claim measurable performance rather than routine excipient combinations.
• Biosimilar risk does not apply because levocetirizine is a small molecule.
• Paragraph IV litigation is mainly relevant to new formulation, combination, delivery, or packaging patents.
• Licensing value is highest where a product has regulatory approval, proven sensory performance, protected formulation claims, or a cost advantage.
• Geographic patent and regulatory analysis must be conducted jurisdiction by jurisdiction.

FAQs About Levocetirizine Excipient Commercialization

Is levocetirizine suitable for an orally disintegrating tablet?

Yes. Levocetirizine’s 5 mg dose is compatible with orally disintegrating tablet development. Mannitol, a superdisintegrant, a taste-masking system, and moisture-protective packaging are common design considerations.

Can levocetirizine oral solution be formulated without parabens?

Yes, but the alternative preservation system must demonstrate antimicrobial effectiveness, chemical compatibility, acceptable taste, and stability across the proposed shelf life and in-use period.

Is a lactose-free levocetirizine tablet commercially differentiated?

It can be, particularly in hospital, mail-order, and consumer channels where lactose avoidance is valued. The differentiation is commercial rather than inherently patent-protected.

Does a new levocetirizine excipient combination require clinical trials?

Not necessarily. The required evidence depends on the regulatory pathway, dosage form, formulation changes, bioequivalence expectations, and product claims. Conventional equivalent products may rely on analytical and bioequivalence data, while materially different products can require broader clinical support.

Which levocetirizine dosage form has the highest margin potential?

A differentiated pediatric liquid or orally disintegrating tablet generally offers greater margin potential than a standard immediate-release tablet because sensory performance, packaging, and manufacturing controls create higher entry barriers. The market is smaller and development risk is higher.

References

1. U.S. National Library of Medicine. (n.d.). DailyMed: Levocetirizine dihydrochloride tablet, film coated. https://dailymed.nlm.nih.gov/

2. U.S. National Library of Medicine. (n.d.). DailyMed: Levocetirizine dihydrochloride oral solution. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

4. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs